Provided by Tiger Trade Technology Pte. Ltd.

PMV Pharmaceuticals

1.24
-0.0200-1.59%
Post-market: 1.240.00000.00%19:30 EDT
Volume:576.32K
Turnover:710.86K
Market Cap:66.29M
PE:-0.88
High:1.29
Open:1.26
Low:1.20
Close:1.26
52wk High:1.88
52wk Low:1.02
Shares:53.46M
Float Shares:51.66M
Volume Ratio:0.32
T/O Rate:1.12%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4131
EPS(LYR):-1.4800
ROE:-70.93%
ROA:-42.39%
PB:0.93
PE(LYR):-0.84

Loading ...

PMV Pharma Q2 EPS $(0.34) Beats $(0.39) Estimate

Benzinga Earnings
·
Aug 14

PMV Pharma Q2 FY26 Net Loss Narrows 14.73% to $18.09 Million

Reuters
·
Aug 14

PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights

THOMSON REUTERS
·
Aug 14

PMV Pharmaceuticals Q2 Net Income USD -18.086 Million

THOMSON REUTERS
·
Aug 14

PMV Pharmaceuticals Inc Expected to Post a Loss of 39 Cents a Share - Earnings Preview

Reuters
·
Aug 03

PMV Pharmaceuticals Coverage Assumed by Ladenburg Thalmann at Buy

Dow Jones
·
Jul 08

PMV Pharmaceuticals shareholders elect two directors at annual meeting

Reuters
·
Jun 05

PMV Pharmaceuticals (NASDAQ:PMVP) Will Have To Spend Its Cash Wisely

Simply Wall St.
·
May 19

PMV Pharmaceuticals price target lowered to $5 from $6 at Oppenheimer

TIPRANKS
·
May 13

PMV Pharmaceuticals reports Q1 EPS (34c), consensus (38c)

TIPRANKS
·
May 13

PMV Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 12

PMV Pharma Q1 EPS $(0.34) Beats $(0.39) Estimate

Benzinga Earnings
·
May 12

PMV Pharma Q1 FY26 net loss widens to $18 million

Reuters
·
May 12

BRIEF-PMV Pharmaceuticals Q1 EPS USD -0.34

Reuters
·
May 12

PMV Pharmaceuticals Q1 Operating Expenses USD 19.019 Million

THOMSON REUTERS
·
May 12

PMV Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Highlights

GlobeNewswire
·
May 12

PMV Pharmaceuticals Inc expected to post a loss of 41 cents a share - Earnings Preview

Reuters
·
May 05

PMV Pharma names Laurie Stelzer board chair, succeeding Rich Heyman

Reuters
·
Apr 22

PMV Pharmaceuticals announces annual shareholder meeting

Reuters
·
Apr 22

PMV Pharmaceuticals Inc - Anticipates Nda Submission for Rezatapopt in Tp53 Y220c Ovarian Cancer in Q1 2027

THOMSON REUTERS
·
Apr 22